

Supplemental Table S3. Changes in Clinical Characteristics between at Re-Evaluation and 1 Year after Treatment Resumption

| Characteristic | No. | At re-evaluation | One year after treatment resumption | P value |
|------------------------------------|-----|------------------------|-------------------------------------|---------|
| Age, yr | 187 | 18.9±2.9 | 20.0±3.0 | - |
| Height, cm | 183 | 164.0±9.1 | 165.3±9.3 | <0.001 |
| Weight, kg | 181 | 65.2±15.1 | 67.6±15.5 | <0.001 |
| Body mass index, kg/m ² | 181 | 24.1±4.8 | 24.6±4.8 | <0.001 |
| Height Z-score | 183 | -0.70±1.48 | -0.53±1.50 | <0.001 |
| Weight Z-score | 181 | 0.33±1.66 | 0.55±1.64 | <0.001 |
| Body mass index Z-score | 181 | 0.76±1.66 | 0.92±1.66 | 0.001 |
| Overweight/obesity | 181 | 86 (47.5) | 103 (56.9) | 0.002 |
| IGF-1, µg/L | 181 | 79.2±67.8 | 167.0±116.4 | <0.001 |
| IGFBP-3, µg/L | 96 | 1,815.2±699.6 | 2,291.4±909.6 | <0.001 |
| Fasting plasma glucose, mg/dL | 146 | 87.6±12.7 | 93.9±23.7 | 0.001 |
| Glycated hemoglobin, % | 94 | 5.5±0.5 | 5.5±1.0 | 0.171 |
| Prediabetes/diabetes | 88 | 37 (42.0) | 44 (50.0) | 0.230 |
| Total cholesterol, mg/dL | 165 | 183.8±32.8 | 184.3±38.9 | 0.854 |
| Triglyceride, mg/dL | 118 | 155.0±133.9 | 159.6±90.0 | 0.677 |
| HDL cholesterol, mg/dL | 74 | 43.8±13.0 | 47.8±13.3 | 0.003 |
| LDL cholesterol, mg/dL | 74 | 117.7±32.2 | 112.2±32.1 | 0.126 |
| Non-HDL cholesterol, mg/dL | 74 | 141.7±32.3 | 135.4±33.2 | 0.133 |
| Dyslipidemia | 86 | 59 (68.6) | 55 (64.0) | 0.424 |
| Lumbar spine BMD Z-score | 21 | -1.50 (-2.40 to -0.65) | -1.60 (-2.40 to -0.90) | 0.188 |
| Femoral neck BMD Z-score | 27 | -1.10 (-1.90 to -0.25) | -0.90 (-1.60 to -0.05) | 0.022 |

Values are expressed as mean±standard deviation, number (%), or median (interquartile range).

IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMD, bone mineral density.